Minerva Surgical, a women’s health company focused on the treatment of abnormal uterine bleeding, priced its IPO of 6.25 million shares at $12 per share.
The gross proceeds of the offering are expected to be $75 million. Shares begin trading today on the Nasdaq under UTRS.
The offering is expected to close Oct. 26. The underwriters have a 30-day option to purchase up to an additional 937,500 shares.
J.P. Morgan, Piper Sandler, UBS and SVB Leerink are joint book-running managers for the offering.
